These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 19105960)

  • 21. [Peginterferon-alfa-2b or -alfa-2a and ribavirin combined treatment in hepatitis C infection].
    Szalay F
    Orv Hetil; 2010 Feb; 151(7):271-3. PubMed ID: 20133247
    [No Abstract]   [Full Text] [Related]  

  • 22. [Genotype 1 superresponder treat for only 24 weeks].
    MMW Fortschr Med; 2005 Dec; 147(51-52):69. PubMed ID: 16402717
    [No Abstract]   [Full Text] [Related]  

  • 23. Scleromyxedema secondary to hepatitis C virus and successfully treated with antiviral therapy.
    Smith JA; Kalimullah FA; Erickson CP; Peng LS
    Dermatol Online J; 2015 Sep; 21(9):. PubMed ID: 26437283
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [HIV/HCV double infection: combination is a clear therapy option].
    Reich B
    Dtsch Med Wochenschr; 2004 Jul; 129(28-29):1590. PubMed ID: 15274242
    [No Abstract]   [Full Text] [Related]  

  • 25. Pegylated interferon-alpha2a and ribavirin in HIV-hepatitis C coinfected patients.
    Expert Rev Anti Infect Ther; 2004 Jun; 2(3):341-2. PubMed ID: 15490503
    [No Abstract]   [Full Text] [Related]  

  • 26. [Treatment with pegylated interferon and ribavirin in patients co-infected by human immunodeficiency virus and hepatitis C virus].
    Marcos Sánchez F; Albo Castaño MI; Casallo Blanco S
    Rev Clin Esp; 2007 Mar; 207(3):150-1; author reply 151-2. PubMed ID: 17397643
    [No Abstract]   [Full Text] [Related]  

  • 27. Occurrence of hepatocellular carcinoma 13 years after successful antiviral treatment for HCV infection.
    Puoti C; Lanzetta G; Scotti E
    J Gastrointestin Liver Dis; 2016 Sep; 25(3):408-9. PubMed ID: 27689211
    [No Abstract]   [Full Text] [Related]  

  • 28. Interferon/pegylated interferon and ribavirin in HCV-associated kidney disease with or without cryoglobulinemia.
    Bruchfeld A; Lindahl K; Stahle L; Schvarcz R
    J Hepatol; 2006 Feb; 44(2):432-3; author reply 433. PubMed ID: 16338023
    [No Abstract]   [Full Text] [Related]  

  • 29. Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6.
    Lukasiewicz E; Hellstrand K; Westin J; Ferrari C; Neumann AU; Pawlotsky JM; Schalm SW; Zeuzem S; Veldt BJ; Hansen BE; Verhey-Hart E; Lagging M
    Hepatology; 2007 Jan; 45(1):258-9. PubMed ID: 17187414
    [No Abstract]   [Full Text] [Related]  

  • 30. The course of inactive hepatitis B in hepatitis-C-coinfected patients treated with interferon and ribavirin.
    Viganò M; Aghemo A; Iavarone M; Rumi MG; Agnelli F; Lampertico P; Donato MF; Colombo M
    Antivir Ther; 2009; 14(6):789-96. PubMed ID: 19812441
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV and hepatitis co-infection: a consensus for treatment?
    Lumb J
    Lancet Infect Dis; 2005 Apr; 5(4):202. PubMed ID: 15834972
    [No Abstract]   [Full Text] [Related]  

  • 32. Interferon for hepatitis C patients with psychiatric disorders.
    Rifai MA; Bozorg B; Rosenstein DL
    Am J Psychiatry; 2004 Dec; 161(12):2331-2; author reply 2332-4. PubMed ID: 15569919
    [No Abstract]   [Full Text] [Related]  

  • 33. [Management of hepatitis B virus and hepatitis C virus infection in chronic kidney failure].
    Vallet-Pichard A; Pol S
    Nephrol Ther; 2015 Nov; 11(6):507-20. PubMed ID: 26423779
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rapid virological response to peginterferon and ribavirin for hepatitis C genotype 1: the role of weight-based ribavirin exposure.
    Yu ML; Dai CY; Huang JF; Chuang WL
    Hepatology; 2008 Sep; 48(3):1019-20; author reply 1020-1. PubMed ID: 18756469
    [No Abstract]   [Full Text] [Related]  

  • 35. FDA approves Pegasys and Copegus for hepatitis C in patients with HIV co-infection.
    Bartlett JG
    Hopkins HIV Rep; 2005 May; 17(3):15. PubMed ID: 16419314
    [No Abstract]   [Full Text] [Related]  

  • 36. Hepatitis C virus in the setting of HIV or hepatitis B virus coinfection.
    Sterling RK; Sulkowski MS
    Semin Liver Dis; 2004; 24 Suppl 2():61-8. PubMed ID: 15346248
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of sustained virological response in liver transplant recipients with recurrent hepatitis C virus following combination pegylated interferon alfa-2b and ribavirin therapy using tissue hepatitis C virus reverse transcriptase polymerase chain reaction testing.
    Neff GW; O'Brien CB; Cirocco R; Montalbano M; de Medina M; Ruiz P; Khaled AS; Bejarano PA; Safdar K; Hill MA; Tzakis AG; Schiff ER
    Liver Transpl; 2004 May; 10(5):595-8. PubMed ID: 15108250
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination therapy with interferon-alpha and ribavirin in patients with dual hepatitis B and hepatitis C virus infection.
    Hung CH; Lee CM; Lu SN; Wang JH; Tung HD; Chen CH; Changchien CS
    J Gastroenterol Hepatol; 2005 May; 20(5):727-32. PubMed ID: 15853986
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C.
    Morishima C; Polyak SJ; Ray R; Doherty MC; Di Bisceglie AM; Malet PF; Bonkovsky HL; Sullivan DG; Gretch DR; Rothman AL; Koziel MJ; Lindsay KL;
    J Infect Dis; 2006 Apr; 193(7):931-40. PubMed ID: 16518754
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peginterferon and ribavirin for hepatitis C.
    Abramowicz M
    N Engl J Med; 2007 Mar; 356(12):1270-1; author reply 1271. PubMed ID: 17378100
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.